Source: Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Manuel J. Richter, Athiththan Yogeswaran, Khodr Tello. Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders. Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020 Btk (Bruton’s tyrosine kinase) in B cells is overexpressed in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Increased activity of Lyn tyrosine kinase causes multiple chronic obstructive pulmonary disease-like changes in mouse Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation Source: ERJ Open Res, 5 (4) 00037-2019; 10.1183/23120541.00037-2019 Year: 2019 Rho kinase inhibitors for pulmonary hypertension: waiting for clinical evidence Source: Eur Respir J 2010; 36: 709-711 Year: 2010 The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017 Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity Source: Eur Respir J 2006; 27: 230-232 Year: 2006 The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1426-1433 Year: 2015 Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 Experience of using Janus kinase inhibitors in COVID-19 Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment Year: 2021 Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Role of IκB kinases (IKKs) α and β in severe asthma and COPD Source: Eur Respir J 2005; 26: Suppl. 49, 2s Year: 2005 Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance–pharmacodynamic study Source: Eur Respir J, 53 (5) 1802472; 10.1183/13993003.02472-2018 Year: 2019 Increased activation of p38 MAPK in COPD Source: Eur Respir J 2008; 31: 62-69 Year: 2008 Key roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bed Source: Eur Respir J 2013; 41: 3-4 Year: 2013 The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis Source: Eur Respir Rev 2017; 26: 160004 Year: 2017 Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Pulmonary hypertension in patients with chronic myeloproliferative disorders Source: Eur Respir Rev 2015; 24: 400-410 Year: 2015